Lecanemabの治療効果をアミロイド仮説から紐解く

中野 博人; 小野 賢二郎

doi:10.15082/jsnt.42.3_245

シンポジウム5：アルツハイマー病診療の最前線　～レカネマブ治療の現場から～

Lecanemabの治療効果をアミロイド仮説から紐解く

著者情報

キーワード: Alzheimer disease, amyloid β–proteins, amyloid β protofibrils, amyloid β oligomer, anti–amyloid β–proteins monoclonal antibody

ジャーナルフリー

2025 年 42 巻 3 号 p. 245-248

DOI https://doi.org/10.15082/jsnt.42.3_245

詳細

抄録

Alzheimer disease (AD) is the main cause of dementia worldwide. Extracellular deposition of amyloid β–protein (Aβ) in the brain is a primary event for the pathogenesis of patients with AD. Currently, the development of anti–Aβ monoclonal antibodies is at the center of AD treatment. This article discusses the therapeutic efficacy of lecanemab, which is a pioneer of anti–Aβ monoclonal antibody medication, based on the Aβ cascade hypothesis.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）